This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Share
Stay up to date

Home
Topics
Videos
Infographics
Articles
Case Studies
Faculty
Stay up to date

Low-density Lipoprotein Cholesterol Articles

Articles
Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT
Shah NP, McGuire DK, Cannon CP, et al.
Journal:
J Am Heart Assoc

First published: June 22, 2023 DOI: 10.1161/JAHA.122.029593
View
- Share
Articles
Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association
Kirkpatrick CF, Sikand G, Petersen KS, et al.
Journal:
J Clin Lipidol

First published: June 2, 2023 DOI: 10.1016/j.jacl.2023.05.099
View
- Share
Articles
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial
Ballantyne CM, Ditmarsch M, Kastelein JJ, et al.
Journal:
J Clin Lipidol

First published: May 31, 2023 DOI: 10.1016/j.jacl.2023.05.098
View
- Share
Articles
Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study
Ray KK, Haq I, Bilitou A, et al.
Journal:
Lancet Reg Health Eur

First published: April 5, 2023 DOI: 10.1016/j.lanepe.2023.100624
View
- Share
Articles
Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020
Jacobs JA, Addo DK, Zheutlin AR, et al.
Journal:
JAMA Cardiol

First published: March 22, 2023 DOI: 10.1001/jamacardio.2023.0228
View
- Share
Articles
Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial
Ballantyne CM, Banka P, Mendez G, et al.
Journal:
J Am Coll Cardiol

First published: March 6, 2023 DOI: 10.1016/j.jacc.2023.02.018
View
- Share
Articles
Early initiation of PCSK9 inhibition in myocardial infarction could be EPIC for patient care
Bhatt DL
Journal:
EuroIntervention

First published: December 2, 2022 DOI: 10.4244/EIJ-E-22-00047
View
- Share
Articles
Knowledge of HbA1c and LDL-C treatment goals, subjective level of disease-related information and information needs in patients with atherosclerotic cardiovascular disease
Brockmeyer M, Wies E, Joerges J, et al.
Journal:
Clin Cardiol

First published: November 30, 2022 DOI: 10.1002/clc.23948
View
- Share

How would you rate this content?

Privacy Policy
Terms of use
Stay up to date
Cookie Preferences
This Knowledge Hub is supported by Novartis.

Low-density Lipoprotein Cholesterol Articles

Articles

Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT

Shah NP, McGuire DK, Cannon CP, et al.

Articles

Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association

Kirkpatrick CF, Sikand G, Petersen KS, et al.

Articles

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

Ballantyne CM, Ditmarsch M, Kastelein JJ, et al.

Articles

Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study

Ray KK, Haq I, Bilitou A, et al.

Articles

Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020

Jacobs JA, Addo DK, Zheutlin AR, et al.

Articles

Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial

Ballantyne CM, Banka P, Mendez G, et al.

Articles

Early initiation of PCSK9 inhibition in myocardial infarction could be EPIC for patient care

Bhatt DL

Articles

Knowledge of HbA1c and LDL-C treatment goals, subjective level of disease-related information and information needs in patients with atherosclerotic cardiovascular disease

Brockmeyer M, Wies E, Joerges J, et al.

Articles

Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT

Shah NP, McGuire DK, Cannon CP, et al.

Share

Articles

Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association

Kirkpatrick CF, Sikand G, Petersen KS, et al.

Share

Articles

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

Ballantyne CM, Ditmarsch M, Kastelein JJ, et al.

Share

Articles

Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study

Ray KK, Haq I, Bilitou A, et al.

Share

Articles

Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020

Jacobs JA, Addo DK, Zheutlin AR, et al.

Share

Articles

Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial

Ballantyne CM, Banka P, Mendez G, et al.

Share

Articles

Early initiation of PCSK9 inhibition in myocardial infarction could be EPIC for patient care

Bhatt DL

Share

Articles

Knowledge of HbA1c and LDL-C treatment goals, subjective level of disease-related information and information needs in patients with atherosclerotic cardiovascular disease

Brockmeyer M, Wies E, Joerges J, et al.

Share